)
Visual
test
Palatin Technologies
Palatin Technologies (PTN) investor relations material
Palatin Technologies Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary6 Mar, 2026
Technology platform and therapeutic focus
Specializes in melanocortin system targeting for obesity, rare MC4R diseases, and inflammatory/autoimmune conditions.
First to gain FDA approval for a melanocortin agent (Vyleesi® for female sexual dysfunction).
Leverages expertise in melanocortin biology and chemistry for multiple therapeutic opportunities.
Leadership and team
Leadership team has extensive experience in drug research, development, finance, operations, and business development.
Key executives have backgrounds from major pharma companies and decades of industry experience.
MC4R obesity programs and pipeline
Developing next-generation MC4R agonists: oral small molecule (PL7737) and once-weekly peptide for rare MC4R pathway diseases (HO, PWS).
PL7737 granted FDA orphan drug designation for obesity due to leptin receptor deficiency.
PL7737 shows significant, dose-dependent weight loss in preclinical models without hyperpigmentation.
IND submission for PL7737 planned for 1H 2026; Phase 1 and 2/3 studies in HO and PWS patients targeted for late 2026.
Once-weekly peptide agonist IND enabling studies planned for 2H 2026, with clinical studies in 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Palatin Technologies
- MC4R-based obesity pipeline advances with strong cash reserves and clinical trials set for 2026.PTN
Q2 202627 Feb 2026 - Advancing MC4R agonists for rare obesity and forging key partnerships for future growth.PTNCorporate presentation17 Feb 2026
- Net loss of $29.7M, asset sale, and pipeline progress set stage for key 2024–2025 milestones.PTNQ4 202419 Jan 2026
- No product revenue, $7.8M net loss, and a strategic pivot to obesity programs with key data due in 2025.PTNQ1 202514 Jan 2026
- Net loss narrowed, no product revenue, and liquidity risks persist amid advancing clinical programs.PTNQ2 202524 Dec 2025
- Shareholders to vote on director elections, reverse split, warrants, and executive pay.PTNProxy Filing1 Dec 2025
- Shareholders to vote on director elections, reverse split, warrants, and equity plan changes.PTNProxy Filing1 Dec 2025
- Highly dilutive best-efforts offering seeks urgent capital to fund clinical programs and avoid delisting.PTNRegistration Filing29 Nov 2025
- Biopharma firm seeks up to $9.1M from warrant exercises amid financial and listing challenges.PTNRegistration Filing29 Nov 2025
Next Palatin Technologies earnings date
Q3 202613 May, 2026
Palatin Technologies
Next Palatin Technologies earnings date
Q3 202613 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage